Skip to main content
Erschienen in: Current Pain and Headache Reports 6/2014

01.06.2014 | Cancer Pain (D Marcus, Section Editor)

Breakthrough Cancer Pain

verfasst von: Andrew N. Davies

Erschienen in: Current Pain and Headache Reports | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Breakthrough pain is a distinct pain state that is common in patients with cancer pain and which is associated with significant morbidity in this group of patients. The aim of this article is to highlight important journal articles relating to breakthrough pain that have been published within the last year, including a systematic review of the epidemiology of breakthrough pain, the largest-ever study of the clinical features of breakthrough pain, and a network meta-analysis of the treatment of breakthrough pain.
Literatur
1.
Zurück zum Zitat Portenoy RK, Hagen NA. Breakthrough pain: definition and management. Oncol Huntingt. 1989;3(8 Suppl):25–9. Portenoy RK, Hagen NA. Breakthrough pain: definition and management. Oncol Huntingt. 1989;3(8 Suppl):25–9.
2.
Zurück zum Zitat Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273–81.PubMedCrossRef Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273–81.PubMedCrossRef
3.••
Zurück zum Zitat Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331–8. Expert (UK) recommendations on diagnosis and management of breakthrough pain.PubMedCrossRef Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331–8. Expert (UK) recommendations on diagnosis and management of breakthrough pain.PubMedCrossRef
4.•
Zurück zum Zitat Deandrea S, Corli O, Consonni D, et al. Prevalence of breakthrough cancer pain: a systematic review and pooled analysis of published literature. J Pain Symptom Manag. 2014;47:57–76. First systematic review of the prevalence of breakthrough cancer pain in the literature.CrossRef Deandrea S, Corli O, Consonni D, et al. Prevalence of breakthrough cancer pain: a systematic review and pooled analysis of published literature. J Pain Symptom Manag. 2014;47:57–76. First systematic review of the prevalence of breakthrough cancer pain in the literature.CrossRef
5.
Zurück zum Zitat Portenoy RK. Treatment of temporal variations in chronic cancer pain. Semin Oncol. 1997;5(S16):7–12. Portenoy RK. Treatment of temporal variations in chronic cancer pain. Semin Oncol. 1997;5(S16):7–12.
6.
Zurück zum Zitat Mercadante S, Zagonel V, Breda E, et al. Breakthrough pain in oncology: a longitudinal study. J Pain Symptom Manag. 2010;40:183–90.CrossRef Mercadante S, Zagonel V, Breda E, et al. Breakthrough pain in oncology: a longitudinal study. J Pain Symptom Manag. 2010;40:183–90.CrossRef
7.••
Zurück zum Zitat Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manag. 2013;46:619–28. Largest study of the clinical features of breakthrough cancer pain in the literature.CrossRef Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manag. 2013;46:619–28. Largest study of the clinical features of breakthrough cancer pain in the literature.CrossRef
8.•
Zurück zum Zitat Bedard G, Hawley P, Zhang L, et al. A survey of Canadian cancer patients’ perspectives on the characteristics and treatment of breakthrough pain. Support Care Cancer. 2013;21:2557–63.PubMedCrossRef Bedard G, Hawley P, Zhang L, et al. A survey of Canadian cancer patients’ perspectives on the characteristics and treatment of breakthrough pain. Support Care Cancer. 2013;21:2557–63.PubMedCrossRef
9.
Zurück zum Zitat Saini A, Tucci M, Tampellini M, et al. Circadian variation of breakthrough pain in cancer patients. Eur J Pain. 2013;17:264–70.PubMedCrossRef Saini A, Tucci M, Tampellini M, et al. Circadian variation of breakthrough pain in cancer patients. Eur J Pain. 2013;17:264–70.PubMedCrossRef
10.
Zurück zum Zitat Fine PG, Busch MA. Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manag. 1998;16:179–83.CrossRef Fine PG, Busch MA. Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manag. 1998;16:179–83.CrossRef
11.
Zurück zum Zitat Bruera E, Macmillan K, Kuehn N, Miller MJ. Circadian distribution of extra doses of narcotic analgesics in patients with cancer pain: a preliminary report. Pain. 1992;49:311–4.PubMedCrossRef Bruera E, Macmillan K, Kuehn N, Miller MJ. Circadian distribution of extra doses of narcotic analgesics in patients with cancer pain: a preliminary report. Pain. 1992;49:311–4.PubMedCrossRef
12.
Zurück zum Zitat Citron ML, Kalra JM, Seltzer VL, Chen S, Hoffman M, Walczak MB. Patient-controlled analgesia for cancer pain: a long term study of inpatient and outpatient use. Cancer Investig. 1992;10:335–41.CrossRef Citron ML, Kalra JM, Seltzer VL, Chen S, Hoffman M, Walczak MB. Patient-controlled analgesia for cancer pain: a long term study of inpatient and outpatient use. Cancer Investig. 1992;10:335–41.CrossRef
13.
Zurück zum Zitat Davies A. Cancer-related Breakthrough Pain. 2nd ed. Oxford: Oxford University Press; 2012.CrossRef Davies A. Cancer-related Breakthrough Pain. 2nd ed. Oxford: Oxford University Press; 2012.CrossRef
14.••
Zurück zum Zitat Zeppetella G, Davies A, Rios C, Eijgelshoven I, Jansen JP. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manag. 2013. doi:10.1016/j.jpainsymman.2013.05.020. Most complete and up-to-date network analysis of the efficacy of rescue medication for breakthrough cancer pain in the literature. Zeppetella G, Davies A, Rios C, Eijgelshoven I, Jansen JP. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manag. 2013. doi:10.​1016/​j.​jpainsymman.​2013.​05.​020. Most complete and up-to-date network analysis of the efficacy of rescue medication for breakthrough cancer pain in the literature.
15.
Zurück zum Zitat Vissers D, Stam W, Nolte T, Lenre M, Jansen J. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin. 2010;26:1037–45.PubMedCrossRef Vissers D, Stam W, Nolte T, Lenre M, Jansen J. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin. 2010;26:1037–45.PubMedCrossRef
16.
Zurück zum Zitat Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manag. 2013. doi:10.1016/j.jpainsymman.2012.09.009. Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manag. 2013. doi:10.​1016/​j.​jpainsymman.​2012.​09.​009.
17.
Zurück zum Zitat Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998;90:611–6.PubMedCrossRef Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998;90:611–6.PubMedCrossRef
18.
Zurück zum Zitat Coluzzi PH, Schwartzberg L, Conroy Jr JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001;91:123–30.PubMedCrossRef Coluzzi PH, Schwartzberg L, Conroy Jr JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001;91:123–30.PubMedCrossRef
19.
Zurück zum Zitat Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805–11.PubMedCrossRef Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805–11.PubMedCrossRef
20.
Zurück zum Zitat Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007;5:327–34.PubMed Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007;5:327–34.PubMed
21.
Zurück zum Zitat Kress HG, Oronska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009;31:1177–91.PubMedCrossRef Kress HG, Oronska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009;31:1177–91.PubMedCrossRef
22.
Zurück zum Zitat Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. 2009;25:2805–15.PubMed Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. 2009;25:2805–15.PubMed
23.
Zurück zum Zitat Fallon M, Reale C, Davies A, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol. 2011;9:224–31.PubMedCrossRef Fallon M, Reale C, Davies A, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol. 2011;9:224–31.PubMedCrossRef
24.
Zurück zum Zitat Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877–85.PubMedCrossRef Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877–85.PubMedCrossRef
25.
Zurück zum Zitat Portenoy RK, Burton AW, Gabrail N, Taylor D. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain. 2010;151:617–24.PubMedCrossRef Portenoy RK, Burton AW, Gabrail N, Taylor D. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain. 2010;151:617–24.PubMedCrossRef
26.
Zurück zum Zitat Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010;21:1308–14.PubMedCentralPubMedCrossRef Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010;21:1308–14.PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Rauck R, Reynolds L, Geach J, et al. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2012;28:859–70.PubMedCrossRef Rauck R, Reynolds L, Geach J, et al. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2012;28:859–70.PubMedCrossRef
28.
Zurück zum Zitat Mercadante S, Porzio G, Alelli F, Averna L, Ficorella C, Casuccio A. The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting. Support Care Cancer. 2013;21:2335–9.PubMedCrossRef Mercadante S, Porzio G, Alelli F, Averna L, Ficorella C, Casuccio A. The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting. Support Care Cancer. 2013;21:2335–9.PubMedCrossRef
30.
Zurück zum Zitat Davies AN, Vriens J, Kennett A, McTaggart M. An observational study of oncology patients’ utilisation of breakthrough pain medication. J Pain Symptom Manag. 2008;35:406–11.CrossRef Davies AN, Vriens J, Kennett A, McTaggart M. An observational study of oncology patients’ utilisation of breakthrough pain medication. J Pain Symptom Manag. 2008;35:406–11.CrossRef
31.
Zurück zum Zitat Davies AN, Zeppetella G, Andersen S, et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011;15:756–63.PubMedCrossRef Davies AN, Zeppetella G, Andersen S, et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011;15:756–63.PubMedCrossRef
Metadaten
Titel
Breakthrough Cancer Pain
verfasst von
Andrew N. Davies
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Current Pain and Headache Reports / Ausgabe 6/2014
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-014-0420-9

Weitere Artikel der Ausgabe 6/2014

Current Pain and Headache Reports 6/2014 Zur Ausgabe

Uncommon Headache Syndromes (J Ailani, Section Editor)

Low-Pressure/Spinal Fluid Leak Headache

Childhood and Adolescent Headache (S Evers, Section Editor)

Preventive Drugs in Childhood and Adolescent Migraine

Uncommon Headache Syndromes (J Ailani, Section Editor)

It IS a Tumor- Current Review of Headache and Brain Tumor

Anesthetic Techniques in Pain Management (D Wang, Section Editor)

Ultrasound-Guided Stellate Ganglion Block: Safety and Efficacy

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.